Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | PKM | P14618 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30668014 | 1.00 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL31026209 | 0.84 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL29502585 | 0.82 | NPSR1 (0.54) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL117827 | 0.82 | NPSR1 (0.54) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL29556424 | 0.81 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL118992 | 0.81 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL17611040 | 0.81 | NPSR1 (0.44) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL30641345 | 0.81 | ALDH1A1 (0.47) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL16505254 | 0.81 | ALDH1A1 (0.47) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL12338897 | 0.79 | NPSR1 (0.50) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| WO-2025056065-A1 | CHEMOKINE RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION, AND USE | 上海医药集团股份有限公司 | 2025-03-20 | — | — | WO | disclosed |
| CN-119546602-A | Pyrrolidone derivatives as inhibitors of nfkb-induced kinase | 詹森药业有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2023217906-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-10450314-B2 | Pteridine derivatives as modulators of ROR gamma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-22 | — | — | US | disclosed |
| EP-3356366-B1 | PTERIDINE DERIVATIVES AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2019-08-28 | — | — | EP | disclosed |
| US-20170273985-A1 | TRICYCLIC DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| US-20170273985-A1 | TRICYCLIC DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| WO-2016042775-A1 | TRICYCLIC DERIVATIVE | SUNOVION PHARMACEUTICALS INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016042775-A1 | TRICYCLIC DERIVATIVE | SUNOVION PHARMACEUTICALS INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2370407-B1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| EP-2370407-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010080474-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | JAK2, JAK1, JAK3 | NPSR1 3601/4885KDM4E 928/4885ALDH1A1 1464/4885 |
| US-20170273985-A1 | TRICYCLIC DERIVATIVE | PDE3A, PDE2A, PDE5A | NPSR1 3727/4885KDM4E 2619/4885ALDH1A1 497/4885 |
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | NPSR1 4026/4885KDM4E 1355/4885ALDH1A1 4167/4885 |
| US-10450314-B2 | Pteridine derivatives as modulators of ROR gamma | RORB, RORC, RORA | NPSR1 868/4885KDM4E 1125/4885ALDH1A1 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.